T2 Biosystems Inc (NASDAQ: TTOO)’s stock price has soared by 14.12 in relation to previous closing price of 2.94. Nevertheless, the company has seen a gain of 23.35% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-24 that LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Is It Worth Investing in T2 Biosystems Inc (NASDAQ: TTOO) Right Now?
The 36-month beta value for TTOO is at 0.09. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TTOO is 0.12M, and currently, shorts hold a 312.07% of that float. The average trading volume for TTOO on May 01, 2024 was 288.48K shares.
TTOO’s Market Performance
The stock of T2 Biosystems Inc (TTOO) has seen a 23.35% increase in the past week, with a 12.58% rise in the past month, and a -23.23% fall in the past quarter. The volatility ratio for the week is 11.00%, and the volatility levels for the past 30 days are at 10.84% for TTOO. The simple moving average for the past 20 days is 14.12% for TTOO’s stock, with a -71.84% simple moving average for the past 200 days.
Analysts’ Opinion of TTOO
Many brokerage firms have already submitted their reports for TTOO stocks, with Alliance Global Partners repeating the rating for TTOO by listing it as a “Neutral.” The predicted price for TTOO in the upcoming period, according to Alliance Global Partners is $2.40 based on the research report published on January 27, 2021 of the previous year 2021.
BTIG Research, on the other hand, stated in their research note that they expect to see TTOO reach a price target of $2.50. The rating they have provided for TTOO stocks is “Buy” according to the report published on October 08th, 2020.
TTOO Trading at -11.86% from the 50-Day Moving Average
After a stumble in the market that brought TTOO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.21% of loss for the given period.
Volatility was left at 10.84%, however, over the last 30 days, the volatility rate increased by 11.00%, as shares surge +13.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.44% lower at present.
During the last 5 trading sessions, TTOO rose by +23.35%, which changed the moving average for the period of 200-days by -69.86% in comparison to the 20-day moving average, which settled at $2.96. In addition, T2 Biosystems Inc saw -46.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TTOO starting from CR Group L.P., who sale 7,148,945 shares at the price of $0.16 back on Sep 28 ’23. After this action, CR Group L.P. now owns 0 shares of T2 Biosystems Inc, valued at $1,125,959 using the latest closing price.
CR Group L.P., the 10% Owner of T2 Biosystems Inc, sale 5,981,202 shares at $0.19 during a trade that took place back on Sep 27 ’23, which means that CR Group L.P. is holding 571,796 shares at $1,145,998 based on the most recent closing price.
Stock Fundamentals for TTOO
Current profitability levels for the company are sitting at:
- -6.9 for the present operating margin
- -1.15 for the gross margin
The net margin for T2 Biosystems Inc stands at -7.25. The total capital return value is set at 2.33.
Based on T2 Biosystems Inc (TTOO), the company’s capital structure generated 2.31 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at -1.77. The interest coverage ratio of the stock is -15.99.
Currently, EBITDA for the company is -46.29 million with net debt to EBITDA at -0.68. When we switch over and look at the enterprise to sales, we see a ratio of 7.27. The receivables turnover for the company is 5.07for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.45.
Conclusion
In conclusion, T2 Biosystems Inc (TTOO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
